
Benefits of Treating Hemophilia with Factor Concentrate
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy.
Learn more about different treatment options for hemophilia with the World Federation of Hemophilia Shared Decision Making tool!
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.

In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted

Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and

This monograph provides guidelines for the production of single-donor cryoprecipitate.